Ignite Creation Date:
2025-12-24 @ 7:00 PM
Ignite Modification Date:
2026-05-07 @ 9:00 PM
Study NCT ID:
NCT02393157
Status:
RECRUITING
Last Update Posted:
2025-08-08
First Post:
2015-03-08
Is Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
Obinutuzumab and ICE Chemotherapy in Refractory/Recurrent CD20+ Mature NHL
Sponsor:
New York Medical College
Organization:
Organization Data
Organization:
Class:
OTHER
Study ID:
L-11,392
Study Type:
None
Study Domain:
None
Study Link:
None
Lead Sponsor:
Lead Sponsor Class:
OTHER
Responsible Party:
Responsible Party Title:
Responsible Party Type:
PRINCIPAL_INVESTIGATOR
Responsible Party Affiliation:
Old Name:
None
Old Organization:
None
Collaborators
Collaborators
| Name | Class | View |
|---|---|---|
| None | OTHER | View |